Edward Grahame
About Edward Grahame
Edward Grahame is a Product Development Scientist at Precision NanoSystems Inc. in Glasgow, Scotland, with a focus on non-viral drug-delivery systems and gene transfection for fibrotic lung disease.
Work at Precision NanoSystems
Edward Grahame has been employed as a Product Development Scientist at Precision NanoSystems Inc. since 2020. He is based in Glasgow, Scotland, United Kingdom. In this role, he focuses on advancing non-viral drug-delivery systems and gene transfection techniques, particularly for the treatment of fibrotic lung disease. His work involves collaboration with various stakeholders in the pharmaceutical industry to ensure the successful development of innovative therapeutic solutions.
Education and Expertise
Edward Grahame completed his doctorate at the Institute of Infection, Immunity and Inflammation at the University of Glasgow in August 2016. His educational background includes a Bachelor of Science with Honours in Chemistry from the University of Strathclyde, which he obtained from 2006 to 2010. He also holds a Master of Research in Cell and Proteomic Technologies from the University of Glasgow, completed from 2011 to 2012. His academic training provides a solid foundation for his expertise in drug delivery and gene therapy.
Background
Before joining Precision NanoSystems, Edward Grahame worked in various roles within academic and industry settings. He served as a Development Scientist at Lamellar Biomedical Limited from 2017 to 2020. Prior to that, he was a Research Assistant at the University of Glasgow for eight months in 2016. His experience also includes a four-year tenure as a PhD student in Infection Biology at the University of Glasgow from 2012 to 2016.
Professional Experience
Edward Grahame has extensive experience in managing relationships with collaborators, consultants, and contractors in the pharmaceutical industry. His professional journey has equipped him with the skills necessary to navigate complex project dynamics and foster effective communication among diverse teams. This experience is critical in his current role, where collaboration is essential for the development of innovative drug delivery systems.